References
- Alsukait
SF, Alshamlan NM, Alhalees ZZ, et al. Topical corticosteroids
knowledge, attitudes, and practices of primary care physicians. Saudi
Med J 2017; 38:662–5.
- Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence
of topical glucocorticoids. Eur J Pharm Biopharm 2008; 68:453–66.
- Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical
glucocorticosteroids. J Am Acad Dermatol 2006; 54:1–15.
- Cornell RC. Clinical trials of topical corticosteroids in psoriasis:
correlations with the vasoconstrictor assay. Int J Dermatol 1992; 31
Suppl 1:38–40.
- Haria M, Balfour JA. Methylprednisolone Aceponate. Clin Immunother
1995; 3:241–53.
- McEvoy G, Miller J, Snow E, et al., eds. Metronidazole. In: AHFS Drug
Information. Bethesda, MD, American Society of Health-System
Pharmacists, 2004; 3314–20.
- Kirkland R, Pearce DJ, Balkrishnan R, Feldman SR. Critical factors
determining the potency of topical corticosteroids. J Dermatolog Treat
2006; 17:133–5.
- Goa KL. Clinical pharmacology and pharmacokinetic properties of
topically applied corticosteroids. Drugs 1988; 36:51–61.
- Simpson EL. Atopic dermatitis: a review of topical treatment options.
Curr Med Res Opin 2010; 26:633–40.
- Humbert P, Guichard A. The topical corticosteroid classification
called into question: towards a new approach. Exp Dermatol 2015;
24:393–5.
- Green C, Colquitt J, Kirby J, et al. Clinical and cost-effectiveness
of once-daily versus more frequent use of same potency topical
corticosteroids for atopic eczema: a systematic review and economic
evaluation. Health Technol Assess (Rockv) 2004; 8:iii,iv, 1-120.
- Fusaro RM. Flexible classification for the clinical potency of topical
corticosteroid proprietaries. Drug Intell Clin Pharm 1988; 22:412–5.
- Oakley A. Topical steroid. DermNet NZ. 2016. Available at:
https://dermnetnz.org/topics/topical-steroid/ (accessed on Jan 17,
2022).
- Kerscher M, Williams S, Lehmann P. Topical Treatment with
Glucocorticoids. In: Handbook of Atopic Eczema (Ring J, Przybilla B,
Ruzicka T, eds). Berlin, Heidelberg, Springer Berlin Heidelberg, 2006;
477–91.
- Camarasa JG, Giménez-Arnau A. Corticosteroids: topical. In: European
Handbook of Dermatological Treatments (Katsambas AD, Lotti TM, eds).
Berlin, Heidelberg, Springer Berlin Heidelberg, 2003; 731–8.
- Keida T, Hayashi N, Kawashima M. Application of the Food and Drug
Administration (FDA) bioequivalent guidance of topical dermatological
corticosteroid in yellow-skinned Japanese population: Validation study
using a chromameter. J Dermatol 2006; 33:684–91.
- Kanfer I, Tettey-Amlalo RNO, Au WL, Hughes-Formella B. Assessment of
topical dosage forms intended for local or regional activity. In:
Generic Drug Product Development: Specialty Dosage Forms (Shargel L,
Kanfer I, eds). New York, NY, Informa Healthcare USA, Inc., 2016;
54–103.
- Olsen EA. A double-blind controlled comparison of generic and
trade-name topical steroids using the vasoconstriction assay. Arch
Dermatol 1991; 127:197–201.
- Stoughton RB, Wullich K. The same glucocorticoid in brand-name
products. Does increasing the concentration result in greater topical
biologic activity? Arch Dermatol 1989; 125:1509–11.
- Ference JD, Last AR. Choosing topical corticosteroids. Am Fam
Physician 2009; 79:135–40.
- Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay
and clinical activity in psoriasis. Arch Dermatol 1985; 121:63–7.
- US Food and Drug Administration.
Guidance for Industry: Topical Dermatologic Corticosteroids—In Vivo
Bioequivalence; FDA: Silver Spring, MD, USA, 1995. Available at:
https://www.fda.gov/media/70931/download (accessed on Jan 17, 2022).
- Topical corticosteroids. In:
British National Formulary, 78th ed. London, British Medical
Association and Royal Pharmaceutical Society of Great Britain, 2019;
1241–2.
- Topical Steroid Potencies. Available at:
https://www.empr.com/home/clinical-charts/topical-steroid-potencies/
(accessed on Jan 17, 2022).
- Allenby CF, Sparkes CG. Halogenation and topical corticosteroids: a
comparison between the 17-butyrate esters of hydrocortisone and
clobetasone in ointment bases. Br J Dermatol 1981; 104:179–83.
- Zvidzayi
M, Rath S, Bon C, et al. A Novel Approach to Assess the Potency of
Topical Corticosteroids. Pharmaceutics 2021; 13.
- Kanfer I, Maibach H. The Vasoconstrictor Assay (VCA): Then and Now.
In: Drug Delivery Approaches: Perspectives from Pharmacokinetics and
Pharmacodynamics (Berner B, Gordi T, Benson H, Roberts M, eds).
Hoboken, NJ, John Wiley & Sons, Inc., 2021.
- Kanfer I. Methods for the Assessment of Bioequivalence of Topical
Dosage Forms: Correlations, Optimization Strategies, and Innovative
Approaches. In: Topical Drug Bioavailability, Bioequivalence, and
Penetration (Shah VP, Maibach HI, Jenner J, eds), 2nd ed. New York,
NY, Springer, 2014; 113–51.
- Bonate PL. Recommended reading in population pharmacokinetic
pharmacodynamics. AAPS J 2005; 7:E363–73.
- Ozdin D, Sharma N, Lujan-Zilbermann J, et al. Revisiting FDA’s 1995
Guidance on bioequivalence establishment of topical dermatologic
corticosteroids: new research based recommendations. J Pharm Pharm Sci
2018; 21:413–28.
- Mentré F, Gomeni R. A Two-Step Iterative Algorithm For Estimation In
Nonlinear Mixed-Effect Models With An Evaluation In Population
Pharmacokinetics. J Biopharm Stat 2007; 5:141–58.
- Holford NH, Sheiner LB. Understanding the dose-effect relationship:
clinical application of pharmacokinetic-pharmacodynamic models. Clin
Pharmacokinet 1981; 6:429–53.
- Singh G, Adams W, Lesko L, et al. Development of in vivo
bioequivalence methodology for dermatologic corticosteroids based on
pharmacodynamic modeling. Clin Pharmacol Ther 1999; 66:346–57.